Abstract
Frequencies of peripheral Tregs and Bregs in HCC patients increased after surgery. These results suggest that a postoperative combination of therapies against Tregs and Bregs may be beneficial for better outcome of HCC patients after resection.
Introduction
Surgical resection is the primary treatment for hepatocellular carcinoma (HCC), yet the procedure itself may trigger immunological shifts that favor cancer recurrence. This study explores the perioperative dynamics of regulatory T cells (Tregs) and regulatory B cells (Bregs)—key immune suppressors that can dampen anti-tumor responses. By tracking these cells before and after surgery, researchers aim to identify windows for therapeutic intervention to improve long-term patient outcomes.
Methods
The study followed 36 HCC patients, comparing them with 6 chronic hepatitis B (CHB) patients and 10 healthy donors. Blood samples were analyzed at three time points: pre-surgery (HCCb), 1-2 days post-surgery (HCCa1), and approximately 7 days post-surgery (HCCa7).
- Flow Cytometry: Used to quantify Tregs (CD4+CD25+CD127-) and Bregs (CD19+IL-10+).
- Digital Evaluation Score System (DESS): A novel tool used to digitize 165 clinical variables, allowing for robust statistical correlation between clinical status and immune profiles.
Results
Post-Operative Surge in Regulatory Cells
While HCC patients initially showed lower levels of circulating Tregs and Bregs compared to healthy controls, both populations increased significantly following tumor resection.
Treg frequency rose from 1.14% pre-operatively to 1.38% by day 7 ($P = 0.04$). Bregs showed an even more dramatic increase, rising from 1.88% to 3.48% ($P < 0.001$). This suggests that the physiological stress of surgery or the wound-healing response may inadvertently recruit these suppressive cells.
General Lymphocyte Dynamics
The broader lymphocyte population experienced a sharp decline immediately following surgery, followed by a partial recovery by the end of the first post-operative week.
Clinical and Viral Correlations
Treg levels were positively associated with markers of tumor aggressiveness, such as portal vein tumor thrombosis and advanced clinical stages. In contrast, Breg levels were significantly linked to the patient's viral status, specifically Hepatitis B e Antigen (HBeAg) positivity ($P = 0.03$).
Discussion
The post-operative spike in Tregs and Bregs creates an immunosuppressive environment that may allow residual cancer cells to evade detection. The study's use of the DESS system confirmed that overall disease severity correlates with established staging systems, reinforcing the reliability of these immune observations.
While the study is limited by a relatively small cohort and a short follow-up period, the longitudinal data provides a high-resolution look at immune changes over time. These findings suggest that surgery alone may not be sufficient for long-term HCC management. A "combination therapy" approach, pairing surgical resection with immunotherapies targeting Tregs and Bregs in the immediate post-operative period, could potentially reduce recurrence rates and improve patient outcomes.
Summary updated